ELTX

Elicio Therapeutics Inc.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$189.91M
P/E Ratio
EPS
$-2.36
Beta
1.45
52W High
$14.93
52W Low
$5.80
50-Day MA
$10.95
200-Day MA
$9.91
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Elicio Therapeutics Inc.

Elicio Therapeutics Inc. (ELTX) is a pioneering clinical-stage biotechnology company focused on developing advanced immunotherapy treatments for cancer. Central to its innovative pipeline is the proprietary Amphiphilic TLR9 Agonist, Eli-002, which aims to elicit robust immune responses across multiple cancer types, thereby enhancing patient outcomes. By concentrating on personalized cancer vaccines and state-of-the-art immunotherapeutic approaches, Elicio is strategically positioned to tackle significant unmet medical needs in oncology and is actively progressing its clinical trials to transform cancer treatment paradigms.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-37.38M
Operating Margin0.00%
Return on Equity-1076.00%
Return on Assets-92.40%
Revenue/Share (TTM)$0.00
Book Value$-0.08
Price-to-Book132.74
Price-to-Sales (TTM)
EV/Revenue-
EV/EBITDA-2.61
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$19.09M
Float$13.19M
% Insiders29.76%
% Institutions16.99%

Historical Volatility

HV 10-Day
130.48%
HV 20-Day
95.20%
HV 30-Day
93.96%
HV 60-Day
89.50%
HV Rank
86.1%

Volatility is currently expanding

Analyst Ratings

Consensus ($17.50 target)
2
Buy

More HEALTHCARE Stocks

Data last updated: 5/25/2026